| Item Type | Name |
|
Academic Article
|
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
|
|
Concept
|
Pancreatic Neoplasms
|
|
Academic Article
|
EUS-guided fine needle aspiration with and without trucut biopsy of pancreatic masses.
|
|
Academic Article
|
Update on pancreatic cancer.
|
|
Academic Article
|
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
|
|
Academic Article
|
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
|
|
Academic Article
|
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
|
|
Academic Article
|
A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.
|
|
Academic Article
|
EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results.
|
|
Academic Article
|
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
|
|
Academic Article
|
Novel advances in pancreatic cancer treatment.
|
|
Academic Article
|
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
|
|
Academic Article
|
Advanced or metastatic pancreatic cancer: molecular targeted therapies.
|
|
Academic Article
|
Irinotecan in the management of patients with pancreatic cancer.
|
|
Academic Article
|
EUS visualization and direct celiac ganglia neurolysis predicts better pain relief in patients with pancreatic malignancy (with video).
|
|
Academic Article
|
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
|
|
Academic Article
|
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
|
|
Academic Article
|
A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer.
|
|
Academic Article
|
Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question.
|
|
Academic Article
|
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
|
|
Academic Article
|
Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma.
|
|
Academic Article
|
Advantage of EUS Trucut biopsy combined with fine-needle aspiration without immediate on-site cytopathologic examination.
|
|
Academic Article
|
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
|
|
Academic Article
|
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
|
|
Academic Article
|
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
|
|
Academic Article
|
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
|
|
Academic Article
|
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer.
|
|
Academic Article
|
New directions in the management of advanced pancreatic cancer: a review.
|
|
Academic Article
|
EGFR targeting of solid tumors.
|
|
Academic Article
|
Pancreatic cancer clusters and arsenic-contaminated drinking water wells in Florida.
|
|
Academic Article
|
Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma.
|
|
Academic Article
|
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
|
|
Academic Article
|
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
|
|
Academic Article
|
Emerging cell-cycle inhibitors for pancreatic cancer therapy.
|
|
Academic Article
|
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
|
|
Academic Article
|
Docetaxel in the management of advanced pancreatic cancer.
|